> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-216/
- Published: 2019-03-24T12:00:00.000Z
- Updated: 2026-09-15T01:15:16.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5143693

[**Workshop on Nontuberculous Mycobacterial Disease Drugs**](https://www.fdaweb.com/workshop-on-nontuberculous-mycobacterial-disease-drugs/)  
*Federal Register* notice: FDA announces a 4/8 public workshop entitled “Development of Antibacterial Drugs for the Treatment of Nontuberculous Mycobacterial Disease.” 03/22/2019

[**Antimicrobial Drugs Advisory Committee Meeting on Bacitracin**](https://www.fdaweb.com/antimicrobial-drugs-advisory-committee-meeting-on-bacitracin/)  
*Federal Register* notice: FDA announces a 4/26 Antimicrobial Drugs Advisory Committee meeting to discuss the safety and effectiveness of bacitracin for intramuscular injection for treating infants with pneumonia and empyema caused by staphylococci. 03/22/2019

[**Guide on Pediatric HIV Drug Development**](https://www.fdaweb.com/guide-on-pediatric-hiv-drug-development/)  
*Federal Register* notice: FDA makes available a final guidance entitled “Pediatric HIV Infection: Drug Product Development for Treatment.” 03/20/2019

[**Guide on Pre-Exposure HIV Drug Development**](https://www.fdaweb.com/guide-on-pre-exposure-hiv-drug-development/)  
*Federal Register* notice: FDA makes available a final guidance entitled “Human Immunodeficiency Virus-1 Infection: Developing Systemic Drug Products for Pre-Exposure Prophylaxis.” 03/20/2019

[**Info Collection on Device Symbols in Labeling**](https://www.fdaweb.com/info-collection-on-device-symbols-in-labeling/)  
*Federal Register* notice: FDA seeks comments on an information collection extension for “Medical Devices: Use of Symbols in Labeling — Glossary to Support the Use of Symbols in Labeling.” 03/18/2019

[**Clinical Trial Enrichment Strategies Guide**](https://www.fdaweb.com/clinical-trial-enrichment-strategies-guide/)  
*Federal Register* notice: FDA makes available a final guidance entitled “Enrichment Strategies for Clinical Trials to Support Demonstration of Effectiveness of Human Drugs and Biological Products.” 03/15/2019

[**Guide on Hematologic Disorders Drug Development**](https://www.fdaweb.com/guide-on-hematologic-disorders-drug-development/)  
*Federal Register* notice: FDA makes available a final guidance entitled “Severely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Development of Pharmaceuticals.” 03/15/2019

[**Draft Guide on Clinical Trial Sponsor Monitoring**](https://www.fdaweb.com/draft-guide-on-clinical-trial-sponsor-monitoring/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “A Risk-Based Approach to Monitoring of Clinical Investigations: Questions and Answers.” 03/15/2019